GoKawiil
Tech News
Eli Lilly has struck a cash deal worth as much as $2.875 billion to acquire Merida Biosciences, a biotechnology company. The acquisition is aimed at strengthening Lilly's immunology drug pipeline.
Counterfeit versions of retatrutide, an experimental Eli Lilly weight-loss drug not yet submitted for FDA approval, are being sold at spas and on social media despite lacking any regulatory clearance. The drug targets three hormone receptors to suppress appetite and boost calorie burn, with early trial data suggesting significant weight loss, but no legitimate US provider is authorized to prescribe it. ABC Australia reported a case where a counterfeit vial of the drug caused severe liver damage.